



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No.: 102286.123)

RECEIVED
1614

JUN 05 2001

MAY 09 2001

TECH CENTER 1600/2900

TECH CENTER 1600/2900

Applicant(s): Lechoslaw Turski, et al.

Serial No.: 09/746,662

Examiner: Not Yet Assigned

Filed: December 22, 2000

Group Art Unit: 1614

For: Treatment of Demyelinating Disorders

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

May 3, 2001
Date

Anthony W. Sutton
Anthony W. Sutton

TRANSMITTAL LETTER

Commissioner:

Enclosed for filing are the following documents:

- 1.) Information Disclosure Statement;
- 2.) Copy of the International Search Report;
- 3.) Form PTO-1449, including 15 documents; and
- 4.) Return Postcard.

Please charge any deficiency or credit any overpayment in connection with this matter to Deposit account No. 08-0219.

Date:

May 3, 2001

Respectfully submitted,

Hollie L. Baker

Hollie L. Baker
Reg. No. 31,321
Attorney for Applicants

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6110
Fax: (617) 526-5000

RECEIVED
DEC 18 2001
TECH CENTER 1600/2900



RECEIVED

JUN 04 2001

TECH CENTER 1600/2900

TECH CENTER 1600/2900

RECEIVED
DEC 17 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No.: 102286.123)

Applicant(s): Lechoslaw Turski, et al.

Serial No.: 09/746,662

Examiner: Not Yet Assigned

Filed: December 22, 2000

Group Art Unit: 1614

For: Treatment of Demyelinating Disorders

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

DEC 18 2001

RECEIVED

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

May 3, 2001
Date

Anthony W. Sutton
Anthony W. Sutton

INFORMATION DISCLOSURE STATEMENT

Commissioner:

Applicants and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration.

Pursuant to 37 C.F.R. §§ 1.56 and 1.97-98, Applicant hereby makes of record the documents listed on the attached Form PTO-1449, and encloses copies herewith. Also submitted is a copy of the published PCT International Search Report for the priority application. This application is a continuation of PCT/GB99/02112 filed 7/2/99, which claims priority to GB 9814380, filed 7/2/98 and GB 9824393, filed 11/26/98.

It is respectfully requested that the information above be expressly considered during the prosecution of this application and that the publications be made of record therein and appear among the "References Cited" on any patent to issue therefrom. In this regard, it is requested that the Examiner initial and return a copy of the enclosed Form PTO-1449 with the next Patent Office Communication.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits and is therefore submitted as both timely and proper; therefore, no fees are believed to be due.

The Commissioner, however, is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. 08-0219. A duplicate copy of this sheet is enclosed for that purpose.

Respectfully submitted,

Date: May 3, 2001



Hollie L. Baker
Registration No. 31,321
Attorney for Applicant

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6110
Fax: (617) 526-5000

sutton_anthony Z:\Legal\102286.123\ids_nofee.wpf_wpd.doc

Subt. For, PTO-1449				Docket Number 102286.123		Application Number 09/746,662	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Turski et al.			
				Filing Date December 22, 2000		Group Art Unit 1614	
Sheet	1	OF	1				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,750,525	5/12/1998	Huth et al.	514	249	
	5,597,809	01/28/1997	Dreyer	514	37	

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	EP 0 492 485 B1	07/01/1992	EP	491	04	YES	NO
	DE 4239816 A1	6/01/1994	Germany	37	02		

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
A1	Dusart I et al., "Demyelination, and remyelination by Schwann cells and oligodendrocytes after kainate-induced neuronal depletion in the central nervous system" Neuroscience 1992 51(1): 137-48	
A2	Hewett SJ et al., "Potentiation of oxygen-glucose deprivation-induced neuronal death after induction of iNOS" Stroke 1996 27(9): 1586-91	
A3	Kim W.-G. et al., "AMPA/kainate receptor antagonists reduce lipopolysaccharide (LPS)/interferon-gamma (IFN-gamma)-induced neurotoxicity in mixed cortical neuronal/glial cell cultures" Society for Neuroscience 1998 24(1-2): 1857	
A4	Matute C "Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve" Proc Natl Acad Sci U S A. 1998 95(17): 10229-34	
A5	Matute C et al., "Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes" Proc Natl Acad Sci U S A. 1997 94(16): 8830-5	
A6	McDonald JW et al., "Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity" Nat Med. 1998 4(3): 291-7	
A7	McDonald JW et al., "Multiple classes of the oligodendrocyte lineage are highly vulnerable to excitotoxicity" Neuroreport. 1998 9(12): 2757-62	
A8	McDonald JW et al., "AMPA/ kainate receptor-induced excitotoxicity mediates sublethal myelin injury and death of oligodendrocytes from spinal cord" Society for Neuroscience Abstracts 1998 24(1-2): 465	
A9	Merk Manual, "Demyelinating Cord Disorders" 1992 1507 and 1316	
A10	Miller LG and Fahey JM "Interleukin-1 modulates GABAergic and glutamatergic function in brain" Ann N Y Acad Sci. 1994 739: 292-8	
A11	Rosenberg LJ et al., " 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline reduces glial loss and acute white matter pathology after experimental spinal cord contusion" J Neurosci. 1999 19(1): 464-75	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Title: TREATMENT OF DEMYELINATING DISORDERS

Serial/Patent No. 09/746,662

Applicant TURSKI, et al.

In the above matter, the following have been received by the US Patent and Trademark Office on the date stamped hereon.

- ☐ Express Mail Label No. _____
- ☐ Application incl. _____ pages (☐ Design)
- _____ pp. of specification
- _____ pp. of claims (# of claims - _____)
- _____ pp. of abstract
- _____ sheets of drawings; Figs. _____
- ☐ formal ☐ informal
- ☐ Provisional Application Cover Sheet
- ☐ Declaration / Power of Attorney (☐ Unsigned)
- ☐ Verified Statement Claiming Small Entity Status
- ☐ Copy of Notice to File Missing Parts ☐ Response
- ☐ Request for filing CPA; 37 CFR 1.53(d)
- ☐ IDS, PTO-1449, and 15 references (Supp. _____)
- ☒ Certificate of Mailing under 37 CFR 1.8(a)
- ☐ Response to Office Action/Restriction Req.
- ☐ Petition for _____ month extension of time
- ☐ Assignment and Cover Sheet
- ☐ Amendment (☐ Preliminary; ☐ After Final)
- ☐ Notice of Appeal
- ☐ Appellant's Brief (triplicate) (☐ Reply Brief)
- ☐ Letter to Chief Draftsperson
- ☐ Issue Fee / ☐ Maintenance Fee Transmittal
- ☐ Sequence listing; ☐ Diskette
- ☒ Transmittal Letter
- ☐ Check for \$ _____; check # _____
- ☐ Deposit Account Authorization \$ _____

☒ other: COPY OF THE INTERNATIONAL SEARCH REPORT

☐ other: _____

Mailing Date: 5/3/01 Docket No. 102286123 Atty/paralegal/secy: AMS

KELLY & SMITH